Clinical trial · Observational
Second Malignant Neoplasms After Childhood ALL Therapy
Second Malignant Neoplasms After Childhood ALL Therapy; An International Ponte di Legno Study
NCT01476462CI-TRIAL-00006983PdL-SMN1completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Development of a second neoplasm (SMN) during or after therapy for childhood acute lymphoblastic leukemia (ALL) is a rare event generally associated with a poor prognosis. In this international study we analyze subtypes of SMN in relation to their initial leukemia characteristics and treatment, and their subsequent overall survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- ALL diagnosed 1980-2007
- description
- Cases of childhood acute lymphoblastic leukemia (ALL) diagnosed between 1980 and 2007 and included in the clinical trials of the participating ALL study groups
Primary outcomes (3)
- measure
- Pattern of SMN subtypes
- timeFrame
- At 20 years from diagnosis
- description
- Pattern of the main groups of SMN and their clinical charactiristics
- measure
- Overall survival by subtype
- timeFrame
- At 10 years from diagnosis of SMN
- description
- Overall survival by the main SMN subtypes (myeloid malignancies, brain tumors, lymphomas, sarcomas, carcinomas, others)
- measure
- Risk factors for development of SMN
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed with childhood acute lymphoblastic leukemia * Diagnosis of second cancer before December 31st 2007 Exclusion Criteria: * Uncertainty if the second cancer has emerged from the same original leukemic clone
References
Publications (0)
Data not yet available
No reference posted for this study.